// App-Quantinova.ai

TPS190 : A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Neeraj Agarwal

Principal Investigators

  • Arun Azad

  • Joan Carles

  • Simon Chowdhury

  • Bradley Alexander McGregor

  • Axel Stuart Merseburger

  • Stephane Oudard

  • Fred Saad

  • Andrey Soares

  • Ashok Panneerselvam

  • Fong Wang

  • Sumanta K. Pal

Medical Centers

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Peter MacCallum Cancer Center, Sydney, Australia

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Guys, Kings and St. Thomas Hospitals, and Sarah Cannon Research Institute, London, United Kingdom

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany

  • Georges Pompidou Hospital, University René Descartes, Paris, France

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Hospital Israelita Albert Einstein, Sao Paulo, Brazil

  • Exelixis, Alameda, CA

Locations

  • United States

  • Australia

  • Spain

  • United Kingdom

  • Germany

  • France

  • Canada

  • Brazil

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Prostate cancer

  • Solid malignancies

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Cabozantinib

  • Enzalutamide

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT04446117

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved